PDF(Pubmed)
Abstract：
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation and c-ros oncogene 1 (ROS1) rearrangement are key genetic alterations and predictive tumor markers for non-small cell lung cancer (NSCLC) and are typically considered to be mutually exclusive. EGFR/ROS1 co-mutation is a rare event, and the standard treatment approach for such cases is still equivocal.
METHODS: Herein, we report the case of a 64-year-old woman diagnosed with lung adenocarcinoma, with concomitant EGFR L858R mutation and ROS1 rearrangement. The patient received two cycles of chemotherapy after surgery, but the disease progressed. Following 1-month treatment with gefitinib, the disease progressed again. However, after switching to crizotinib, the lesion became stable. Currently, crizotinib has been administered for over 53 months with a remarkable treatment effect.
CONCLUSIONS: The efficacy of EGFR tyrosine kinase inhibitors and crizotinib was vastly different in this NSCLC patient with EGFR/ROS1 co-mutation. This report will aid future treatment of such patients.
METHODS: Herein, we report the case of a 64-year-old woman diagnosed with lung adenocarcinoma, with concomitant EGFR L858R mutation and ROS1 rearrangement. The patient received two cycles of chemotherapy after surgery, but the disease progressed. Following 1-month treatment with gefitinib, the disease progressed again. However, after switching to crizotinib, the lesion became stable. Currently, crizotinib has been administered for over 53 months with a remarkable treatment effect.
CONCLUSIONS: The efficacy of EGFR tyrosine kinase inhibitors and crizotinib was vastly different in this NSCLC patient with EGFR/ROS1 co-mutation. This report will aid future treatment of such patients.
摘要：
背景：表皮生长因子受体（EGFR）突变和c-ros癌基因1（ROS1）重排是非小细胞肺癌（NSCLC）的关键遗传改变和预测性肿瘤标志物，通常被认为是相互排斥的。EGFR/ROS1共突变是一种罕见事件，这种情况的标准治疗方法仍然模棱两可。
方法：这里，我们报道了一名64岁女性诊断为肺腺癌的病例，伴随EGFRL858R突变和ROS1重排。患者在手术后接受了两个周期的化疗,但是疾病进展了。吉非替尼治疗1个月后，疾病再次进展。然而,改用克唑替尼后，病变变得稳定。目前,克唑替尼已超过53个月，具有显着的治疗效果。
结论：EGFR酪氨酸激酶抑制剂和克唑替尼在EGFR/ROS1共突变的NSCLC患者中的疗效差异很大。该报告将有助于此类患者的未来治疗。
方法：这里，我们报道了一名64岁女性诊断为肺腺癌的病例，伴随EGFRL858R突变和ROS1重排。患者在手术后接受了两个周期的化疗,但是疾病进展了。吉非替尼治疗1个月后，疾病再次进展。然而,改用克唑替尼后，病变变得稳定。目前,克唑替尼已超过53个月，具有显着的治疗效果。
结论：EGFR酪氨酸激酶抑制剂和克唑替尼在EGFR/ROS1共突变的NSCLC患者中的疗效差异很大。该报告将有助于此类患者的未来治疗。
